The FDA has approved cabozantinib, a multi-targeted tyrosine kinase inhibitor, for the treatment of metastatic medullary thyroid cancer.
The FDA approved cabozantinib (Cometriq), a multi-targeted tyrosine kinase inhibitor, for the treatment of metastatic medullary thyroid cancer (MTC) after a pivotal clinical trial showed that the drug more than doubled progression-free survival (PFS) when compared with a placebo.
Cabozantinib, previously known as XL-184, is an oral therapy that inhibits mutations in MET, VEGFR2, and RET. Early clinical studies showed that by targeting these mutations, cabozantinib was able to kill tumor cells, reduce metastases, and inhibit angiogenesis.
Click here to read the full text of this article.